Inclusion Criteria:  Cohort 1 - Alive Individuals  Men or women 18 years of age or the age of majority for their residential state of the United States, or older, at the time of consent. Histologically or cytologically confirmed advanced stage IIIB-IIIC not amenable to curative approach multi-modality (e.g., chemoradiation and/or surgery) treatment, or stage IV non-small cell lung cancer (NSCLC) Demonstration of having advanced ALK+ NSCLC, as assessed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), next-generation sequencing (NGS) or circulating tumor DNA analysis (ctDNA). For ALK FISH, fusions must have been detected in at least 15% of tumor cells. Willingness to provide clinical and medical information to the study team as required. Willingness to provide archival tumor tissue, if available. Patients may enroll even if no tumor tissue is available. Ability to read, write and communicate in English. Ability to sign a web-based informed consent form.  Cohort 2 - Deceased Individuals  Deceased individuals diagnosed with advanced ALK+ lung cancer at age 18 years or older may be studied on a case by case basis. Inclusion will require availability of adequate archived tissue and release of tissue and records by next of kin, if available.  Exclusion Criteria:  Participants who are unwilling to provide informed consent. Participants who are younger than 18 years of age. Participants who are unable to comply with the study procedures. Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements. Participants who have previously enrolled to the study.